Bone Marrow Transplant – Michael LaPelusa
Background
- Donor selection
- Autologous: self, no matching required
- Allogeneic: non-self, matching based on HLA (more matching -> less GVHD risk)
- Matched-related donor (MRD): fully matched sibling
- Matched-unrelated donor (MUD): From NMDP database
- Haploidentical: Half matched sibling or parent
- Source of stem cells:
- Peripheral blood stem cells (PBSCs) vs bone marrow-derived cells vs umbilical cord
- Timeline for transplant:T -14 d: cell mobilization and collection (G-CSF used to help mobilize stem cells)
- T -8 d to T-3d: conditioning regimen, initiation of GVHD ppx, TLS ppx and sinusoidal obstruction syndrome ppx
- T = 0 d: transplant
- T +7 d to T +30 d: engraftment
Complications/Adverse Effects:
- Infectious: Neutropenic fever, typhlitis, GNR, HSV, respiratory/enteral viruses (adenovirus, RSV, parainfluenza), Aspergillus, Candida
- Non-infectious
- Nausea, vomiting, mucositis
- Cytopenia’s: Transfuse as needed (plt >10, hematocrit >21)
- Hepatic veno-occlusive disease/sinusoidal obstructive syndrome:
- 2/2 cytotoxic venule damage from chemo resulting in thrombi formation
- Diagnosis: T Bili >2, hepatomegaly/RUQ pain, weight gain > 2-5%
- Evaluation: RUQ US with doppler
- Treatment: Per heme attending; Consider defibrotide
- Graft failure – primary (persistent neutropenia without engraftment) or secondary (delayed pancytopenia 2/2 immune phenomena or infection after engraftment)
- Engraftment syndrome:
- Pathophys: PMN recovery -> cytokine storm -> vascular leak
- Symptoms: fever, tachycardia, hypotension, SOB, pulmonary edema, rash, weight gain, bone pain, confusion
- Diagnosis: clinical; Workup specific symptoms
- Treatment: high-dose IV steroids
- Acute GVHD:
- Only in allogenic; Increased risk with more HLA mismatch
- Pathophys: donor T cells attack recipient (Th1-mediated)
- Symptoms: skin rash, cholestatic liver injury, diarrhea
- Treatment: IV steroids (methylprednisolone 1-2mg/kg x 5d)
- If refractory: mycophenolate, etanercept, ruxolitinib, antithymocyte globulin
- Chronic GVHD (typically after T+100d s/p allo)
- Can involve all organs but typically see a scleroderma-like picture (xerophthalmia, xerostomia dysphagia, arthritis, skin changes, malar rash, obliterative bronchiolitis, cholestatic liver injury, cytopenia’s)
- Treatment: steroids (also photophoresis for skin), consider trials of ruxolitinib, ibrutinib, rituximab if refractory
- PTLD